| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 10 Nov 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 |
8-K: Regulation FD Disclosure
August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 05 Aug 2026 | 10-Q |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Co... |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 27 Jul 2026 | SCHEDULE 13G |
| 26 Jun 2026 |
Form 4: Pasternak Andy, Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Stacey Jennifer Evans, Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: West Linda, Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Smith Karen L., Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Walker Luke Nathaniel, Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
Form 4: Kantoff Philip W., Director
Granted 45,000 Stock Option (right to buy) |
| 26 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Context Therapeutics Inc. (the “Company”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corp... |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | SCHEDULE 13G/A |
Loading...